425 related articles for article (PubMed ID: 27389831)
1. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
2. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
3. A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
Hansen C; Björklund T; Petit GH; Lundblad M; Murmu RP; Brundin P; Li JY
Neurobiol Dis; 2013 Aug; 56():145-55. PubMed ID: 23643841
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
5.
Dutta AK; Armstrong C; Luo D; Das B; Spencer B; Rissman RA
ACS Chem Neurosci; 2023 Mar; 14(5):885-896. PubMed ID: 36749600
[TBL] [Abstract][Full Text] [Related]
6. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
7. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
8. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
[TBL] [Abstract][Full Text] [Related]
10. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
11. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
Mandler M; Valera E; Rockenstein E; Weninger H; Patrick C; Adame A; Santic R; Meindl S; Vigl B; Smrzka O; Schneeberger A; Mattner F; Masliah E
Acta Neuropathol; 2014; 127(6):861-79. PubMed ID: 24525765
[TBL] [Abstract][Full Text] [Related]
12. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
[TBL] [Abstract][Full Text] [Related]
13. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
[TBL] [Abstract][Full Text] [Related]
14. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
16. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
[TBL] [Abstract][Full Text] [Related]
17. Age-Dependent Alpha-Synuclein Accumulation and Phosphorylation in the Enteric Nervous System in a Transgenic Mouse Model of Parkinson's Disease.
Zhong CB; Chen QQ; Haikal C; Li W; Svanbergsson A; Diepenbroek M; Li JY
Neurosci Bull; 2017 Oct; 33(5):483-492. PubMed ID: 28924920
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease.
Reyes JF; Ekmark-Léwen S; Perdiki M; Klingstedt T; Hoffmann A; Wiechec E; Nilsson P; Nilsson KPR; Alafuzoff I; Ingelsson M; Hallbeck M
Acta Neuropathol Commun; 2021 Mar; 9(1):46. PubMed ID: 33743820
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
[TBL] [Abstract][Full Text] [Related]
20. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
